Skip to main content
Psychedex

1V-LSD

1-pentanoyllysergic acid diethylamide

1Provenance card

the boundary, as counts

Sources

3131 with DOI

5 strong · 24 moderate · 2 weak

Compilations

12026-04-26T11:32:15.938Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

30last ruled 2026-06-04

0 awaiting a ruling

Issued documents

62026-10-19T20:28:54.898Z

notice · info card · emergency

Searches

241 with no results

queries and counts on the build

Claims checked

7658 supported

58 supported · 18 not

Correspondence

0received

consent field ships in Phase 4

Edges

254

derivations recorded for this entity

Complete over 31 sources, 1 compilation, and 30 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/1v-lsd/archive

Timeline

what happened, newest first — claims, searches and artifacts stay inside Build

  1. 2026-10-19issueIssued emergency
  2. 2026-10-19issueIssued info_card
  3. 2026-10-19issueIssued notice
  4. 2026-09-24srcAbsolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study
  5. 2026-09-24srcReturn of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2'S,4'S)-lysergic acid 2,4-dimethylazetidide (LSZ)
  6. 2026-09-24srcReturn of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775)
  7. 2026-09-24srcReturn of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD)
  8. 2026-09-24srcReturn of the lysergamides. Part VI: Analytical and behavioural characterization of 1-cyclopropanoyl-d-lysergic acid diethylamide (1CP-LSD)
  9. 2026-09-24srcPharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration
  10. 2026-09-24srcReturn of the lysergamides. Part VII: Analytical and behavioural characterization of 1-valeroyl-d-lysergic acid diethylamide (1V-LSD)
  11. 2026-09-24srcAnalytical profile, in vitro metabolism and behavioral properties of the lysergamide 1P-AL-LAD
  12. 2026-09-24srcAnalytical and behavioral characterization of 1-dodecanoyl-LSD (1DD-LSD)
  13. 2026-09-24srcAnalytical and behavioral characterization of 1-hexanoyl-LSD (1H-LSD)
  14. 2026-09-24srcAnalytical and Pharmacological Characterization of 1-(Furan-2-Carbonyl)-LSD (1F-LSD) and Comparison With 1-(Thiophene-2-Carbonyl)-LSD (1T-LSD)
  15. 2026-09-24srcIdentification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products
  16. 2026-09-24srcCrystal Structure of an LSD-Bound Human Serotonin Receptor
  17. 2026-09-24srcEfficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis
  18. 2026-09-24srcValidation of an LC-MS/MS method for the quantitative analysis of 1P-LSD and its tentative metabolite LSD in fortified urine and serum samples including stability tests
  19. 2026-09-24srcPharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD)
  20. 2026-09-24srcCorrelation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species
  21. 2026-09-24srcDetermination of LSD and its metabolites in human biological fluids by HPLC-MS/MS
  22. 2026-09-24srcIdentification of a serotonin/glutamate receptor complex implicated in psychosis
  23. 2026-09-24srcAcute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects
  24. 2026-09-24srcPsychedelics promote plasticity by directly binding to BDNF receptor TrkB
  25. 2026-09-24srcGenetic influence of CYP2D6 on pharmacokinetics and acute subjective effects of LSD in a pooled analysis
  26. 2026-09-24srcNeuropsychological profiles of patients suffering from hallucinogen persisting perception disorder (HPPD): A comparative analysis with psychedelic-using and non-using controls
  27. 2026-09-24srcAssociation of Hallucinogen Persisting Perception Disorder with Trait Neuroticism and Mental Health Symptoms
  28. 2026-09-24srcStability studies of ALD-52 and its homologue 1P-LSD
  29. 2026-09-24srcModification of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method targeting LSD and its primary metabolite (OH-LSD) to include nine LSD analogs
  30. 2026-09-24srcThe pharmacology of lysergic acid diethylamide: a review
  31. 2026-09-24srcPsychedelics and the human receptorome
  32. 2026-09-24srcd-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology
  33. 2026-09-24srcClinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience
  34. 2026-09-24srcHallucinogen-Induced Persisting Perception Disorder: A Case Report
  35. 2026-09-04issueIssued emergency
  36. 2026-09-04issueIssued info_card
  37. 2026-09-04issueIssued notice
  38. 2026-06-04proposal28 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
  39. 2026-06-04publicationPublication — backfill
  40. 2026-04-26revisionRevision 1
  41. 2026-04-26absenceSearched ClinicalTrials.gov for "1V-LSD lysergamide" — no results
  42. 2026-04-26genGeneration — pipeline-v5pipeline-v5
  43. 2026-04-26rungeneration run

The same entries, as forms: six forms.